Table 1.
Baseline characteristics of patients.
| Characteristics | All Patients (N = 149) |
|---|---|
| Age, median years (IQR) | 69 (65–74) |
| Male, N (%) | 78 (52%) |
| AML de novo, N (%) | 121 (81%) |
| Hemoglobin, mean g/dL (±SD) | 9.1 ± 1.4 |
| White blood cell × 103, median (IQR) | 7.9 (2.5–28.8) |
| Platelet × 103, median (IQR) | 52 (26–84) |
| WHO Classification, N (%) | |
| AML with minimal differentiation | 28 (18.8%) |
| Acute myelomonocytic leukemia | 28 (18.8%) |
| AML with myelodysplasia-related changes | 28 (18.8%) |
| AML with maturation | 24 (16.1%) |
| Acute monoblastic and monocytic leukemia | 17 (11.4%) |
| AML without maturation | 12 (8.1%) |
| AML with recurrent genetic abnormalities | 8 (5.3%) |
| Therapy-related myeloid neoplasms | 2 (1.3%) |
| Acute erythroid leukemia | 1 (0.7%) |
| Acute megakaryoblastic leukemia | 1 (0.7%) |
| Cytogenetic risk profile, N (%) | |
| Good | 1 (0.7%) |
| Intermediate | 104 (69.8%) |
| Poor | 26 (17.4%) |
| Not evaluable | 18 (12.1%) |
AML = acute myeloid leukemia, WHO = World Health Organization.